Ciro Pharma Private Limited

March 11, 2025

Facilities/Instruments	Amount (₹ crore)	Rating[1]	Rating Action
Long Term Bank Facilities	120.00	CARE D	Downgraded from CARE BB; Stable
Long Term / Short Term Bank Facilities	20.00	CARE D / CARE D	Downgraded from CARE BB; Stable / CARE A4

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

The revision in rating assigned to the bank facilities of CIRO Pharma Private Limited (CPPL) is on account of delays in interest servicing towards the project term loan rated by CARE Ratings Ltd (CARE). The rating action is in line with CARE's policy on default recognition

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Company's ability to meet the curing period guidelines as stipulated by SEBI by demonstrating a delay free track record.

Analytical approach: Standalone

Outlook: Not Applicable

Detailed description of key rating drivers:

Key weaknesses

Delays in Debt Servicing

There was a delay in interest servicing in the project term loan. As per the latest bank statements there have been instances of delay in interest servicing in its project term loan.

Liquidity: Poor

Liquidity is poor marked by limited cashflow generation as the company has commenced its commercial operations very recently.

Assumptions/Covenants- Not Applicable

Environment, social, and governance (ESG) risks - Nil

Applicable criteria

Definition of Default
Liquidity Analysis of Non-financial sector entities
Rating Outlook and Rating Watch
Manufacturing Companies
Pharmaceuticals
Financial Ratios – Non financial Sector
Short Term Instruments

About the company and industry

Industry classification

Macroeconomic indicator	Sector	Industry	Basic industry
Healthcare	Healthcare	Pharmaceuticals & Biotechnology	Pharmaceuticals

[1]Complete definition of ratings assigned are available at www.careedge.in and other CARE Ratings Limited's publications.

CIRO Pharma Private Limited (CPPL) was incorporated in July 2020, with a focus on manufacturing, formulating, and processing various biopharmaceuticals and antibiotics, particularly life-saving formulations such as anti-cancer products. The company has acquired 6.37 acres of land in Siddipet District, Telangana, for its facility from Telangana State Industrial Infrastructure Corporation Limited (TSIIC Ltd). CPPL aims to initially sell its products domestically through third-party pharmaceutical companies. The company also plans to set up a R&D facility at the same location. The project was initially expected to achieve COD in April 2024. However, due to a change in scope aimed at increasing capacity, the revised project cost, factoring in revised cost now stands at ₹298 crore. The additional cost was funded by the promoters. With the project revision, the revised COD was set for November 2024, which the company successfully achieved.

Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)	March 31, 2024 (A)
Total operating income	0.00	0.00	0.02
PBILDT	-0.30	-0.51	-5.20
PAT	-0.33	-0.68	-5.32
Overall gearing (times)	001	0.64	1.25
Interest coverage (times)	NM	-11.02	-83.27

A: Audited UA: Unaudited NM: Not meaningful; Note: these are latest available financial results

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned and Rating Outlook
Fund-based - LT-Term Loan		-	-	September 2033	120.00	CARE D
LT/ST Fund-based/Non-fund-based-CC/WCDL/OD/LC/BG		-	-	-	20.00	CARE D / CARE D

Annexure-2: Rating history for last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT-Term Loan	LT	120.00	CARE D	-	1)CARE BB; Stable (30-Jan-24)	-	-
2	LT/ST Fund-based/Non-fund-based-CC/WCDL/OD/LC/BG	LT/ST	20.00	CARE D / CARE D	-	1)CARE BB; Stable / CARE A4 (30-Jan-24)	-	-

LT: Long term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities- Not Applicable

Annexure-4: Complexity level of instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	LT/ST Fund-based/Non-fund-based-CC/WCDL/OD/LC/BG	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on complexity levels of rated instruments: CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.

Contact Us

Media Contact	Analytical Contacts
Mradul Mishra Director **CARE Ratings Limited** Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in **Relationship Contact** Saikat Roy Senior Director **CARE Ratings Limited** Phone: 912267543404 E-mail: saikat.roy@careedge.in	Karthik Raj K Director **CARE Ratings Limited** Phone: 080 46625555 E-mail: karthik.raj@careedge.in Mohammed Javed Ansari Assistant Director **CARE Ratings Limited** Phone: 914040020131 E-mail: Mohammed.A@careedge.in Vineeth Mididoddi Analyst **CARE Ratings Limited** E-mail: vineeth.mididoddi@careedge.in

About us:
Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

For detailed Rationale Report and subscription information, please visit www.careedge.in